Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab

Ann Oncol. 2016 Sep;27(9):1813-4. doi: 10.1093/annonc/mdw243. Epub 2016 Jun 20.

Authors

A Heine¹, G Kristiansen², H H Schild³, P Brossart⁴

Affiliations

¹ Medical Clinic III for Oncology, Hematology and Rheumatology.
² Insitute for Pathology.
³ Department for Radiology, University Hospital Bonn, Bonn, Germany.
⁴ Medical Clinic III for Oncology, Hematology and Rheumatology peter.brossart@ukb.uni-bonn.de.

PMID: 27329248
DOI: 10.1093/annonc/mdw243

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Drug Resistance, Neoplasm / drug effects*
Humans
Leiomyosarcoma / diagnostic imaging
Leiomyosarcoma / drug therapy*
Male
Nivolumab
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Programmed Cell Death 1 Receptor
Nivolumab